Coagulation abnormalities in patients with cirrhosis in a tertiary hospital Sangli : A prospective study
Keywords:
Cirrhosis, Prothromobin, Clotting, Coagulation abnormalities, Chronic liver disease,Abstract
Background : The clotting is a multistep process comprised of sequence of events of platelet plug formation , clotting process , clotting process termination and clot removal .Synthesis of clotting factors and clearance of their activation products took place in liver. The magnitude of clinical features and coagulation abnormalities will vary depending on liver dysfunction . Therefore  wide spectrum of abnormalities will be seen in patients of liver cirrhosis.
 Aims and Objectives : To study the various coagulation abnormalities in liver cirrhosis patients. Â
Methodology : This 1 year prospective study was conducted in a tertiary hospital  for the evaluation of the frequency of coagulation abnormalities in patients with cirrhosis of liver. 82 patients presenting with cirrhosis of liver were selected and were evaluated for coagulation profile. The data was collected via questionnaire form and analyzed by SPSS (Statistical Packages for Social Sciences) version  The patients blood were tested for coagulation abnormalities including prothrombin time (PT), activated partial thromboplastin time (aPTT), platelet count .
Results :In the present study, out of 82, fifty (60.9 %)  were males and 32 (39.1 ) %  were females. According to Child’s Pughs classification,37(45.12 % ) cirrhotic patients were in class A, 13 (15.85% ) in class B and 32 (39.02 % ) in class C. The PT was prolonged (mean + SD = 20.67  ± 4.12 sec)  in  44 (53.65 % ) patients, while38 (46.34 %)  patients had normal PT which was less than 14 seconds (mean + SD = 12.13 ± 1.01sec). Activated partial thromboplastin time was prolonged in47 (57.31 % )  patients, while35 (42.68 % ) patients had normal APTT which was less than 40 seconds (mean + SD = 33.05 ±  3.06 sec). PT and APTT were significantly raised in cirrhotic patients.
 Approximately 39%  CLD cases had decreased platelet count. Relative risk of GI bleeding with abnormal clotting tests in CLD cases were weakly positive for PT (RR = 1.02; 95% CI, 0.49-2.10), negative for aPTT (RR=0.83; 95% CI, 0.47-1.45), strongly positive for decreased platelet counts (RR = 1.96; 95% CI, 1.08-3.56) .
 Conclusion : Coagulation abnormalities are commonly seen in cirrhotic liver disease.Decreased platelet count and increased PT and APTT are commonly seen in chronic liver disease. These parameters can be used as prognostic markers.
Â
DOI:Â 10.21276/APALM.1170
References
2.Peck Radosavljevic M. Review article: coagulation disorders in chronic liver disease. Aliment Pharmacol Ther 2007; 26 Suppl 1: 21-8.
3.Rverter JC. Abnormal hemostasis tests and bleeding in chronic liver disease: are they related? Yes. J Thromb heamost 2006; 4: 717-20.
4.Tripodi A. Tests of coagulation in liver disease. Clin Liver Dis 2009; 13: 55-61.
5.Thachil J. Relevance of clotting tests in liver disease. Postgrad Med J 2008; 84: 177-81.
6.Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 649-9.
7.Formen LM, Lucey MR. Predicting the prognosis of chronic liver disease: an evolution from child to MELD. Mayo end-stage liver disease. Hepatology 2001; 33: 473-5.
8.Garrison RN, Cryer HM, Howard DA, Polk HC. Clarification of risk factor for abdominal operations in patients with hepatic cirrhosis. Ann Surg 1984; 199: 648-55.
9.Hedner U, Erhardtsen E. Hemostatic disorders in liver disease. In: Schiff ER, Sorrell MF, Maddrey WC, editors. Diseases of the liver. Philadelphia: Lippincott Williams and Wilkins; 2003; pp 625-35.
10.Lechner K, Niessner H, Thaler E. Coagulation abnormalities in liver disease. Semin Thromb Hemost 1977; 4: 40-56.
11.Bashour FN, Teran JC, Mullen KD. Prevalence of peripheral blood cytopenias (hypersplenism) in patients with non-alcoholic chronic liver disease. Am J Gastroenterol 2000; 95: 2936-9.
12.Schepis F, Camma C, Niceforo D, Magnano A, Pallio S, Cinquegrani M, et al. Which patients with cirrhotic should undergo endoscopic screening for esophageal varices detection? Hepatology 2001; 33: 333-8.
13.Zaman A, Hapke R, Flora K, Rosen HR, Benner K. Factors predicting the presence of esophageal or gastric varices in patients with advanced liver disease. Am J Gastroenterol 1999; 94: 3292-6.
14.Clinical and Laboratory Standards Institute (CLSI). Collection, transport and processing of blood specimens for testing plasma-based coagulation assays and molecular hemostasis assays; approved guideline. 5th ed.H21-A5. Pennsylvania USA; 2008.
15.Clinical and Laboratory Standards Institute (CLSI). Procedure for the Determination of Fibrinogen in Plasma; Approved Guideline.2nd ed.H30-A2.Pennsylvania, USA; 2001.
16.Bukhtiari N, Hussain T, Iqbal M, Malik AM, Qureshi AH, Hussain A. Hepatits B and C single and co-infection in Chronic liver disease and their effect on the disease pattern. J Pak Med Assoc 2003; 53: 136-40.
17.Nidegger D, Ragot S, Berthelemy P, Masliah C, Pilette C, Martin T, et al. Cirrhosis and bleeding: the need for very earlymanagement. J Hepatol 2003; 39: 509-14.
18.Patch D, Armonis A, Sabin C, Christopoulou K, Greenslade L, McCormick A, et al. Single portal pressure measurement predicts survival in cirrhotic patients with recent bleeding. Gut 1999; 44: 264-9.
19.Lecleire S, Di Fiore F, Merle V, Herve S, Duhamel C, Rudelli A, et al. Acute upper gastrointestinal bleeding in patients with liver cirrhosis and in noncirrhotic patients: epidemiology and predictive factors of mortality in a prospective multicenter population-based study. J Clin Gastroenterol 2005; 39: 321-7.
20.Escorsell A, Bordas JM, Castaneda B, Liach J, Garcia-Pagan JC, Rodes J, et al. Predictive value of the variceal pressure response to continued pharmacological therapy in patients with cirrhosis and portal hypertension. Hepatology 2000; 31: 1061-7.
21.Dell'era A, Bosch J. Review article: the relevance of portal pressure and other risk factors in acute gastro-oesophageal variceal bleeding. Aliment Pharmacol Ther 2004; 20 Suppl 3: 8-15.
22.Lisman T, Bongers T, Adelmeijer J, Janssen H, de Maat M, de Groot P, et al. Elevated levels of von Willebrand factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006; 44: 53-61.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Sheetal M Sale, Vaibhav P Mane, Vishrabdha R Pawar, Dajiram G Mote, Sushant N Mohite, Vanisha Dhaka
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access at http://opcit.eprints.org/oacitation-biblio.html).